XOMA (NASDAQ:XOMA) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of XOMA (NASDAQ:XOMA) in a research report report published on Monday morning,Benzinga reports. They currently have a $123.00 target price on the biotechnology company’s stock, up from their previous target price of $117.00.

Separately, StockNews.com raised XOMA from a “sell” rating to a “hold” rating in a research note on Wednesday, August 14th.

XOMA Stock Down 3.0 %

NASDAQ:XOMA opened at $32.43 on Monday. The stock’s fifty day simple moving average is $29.37 and its 200-day simple moving average is $27.37. The firm has a market capitalization of $382.12 million, a P/E ratio of -9.60 and a beta of 0.90. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a 12-month low of $14.77 and a 12-month high of $35.00.

Insider Buying and Selling at XOMA

In related news, CEO Owen Hughes sold 21,881 shares of the firm’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total transaction of $655,335.95. Following the sale, the chief executive officer now directly owns 34,979 shares in the company, valued at $1,047,621.05. This trade represents a 38.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 7.20% of the company’s stock.

Institutional Investors Weigh In On XOMA

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XOMA. BNP Paribas Financial Markets grew its holdings in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares in the last quarter. Geode Capital Management LLC grew its stake in XOMA by 0.6% in the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after purchasing an additional 1,138 shares in the last quarter. Rhumbline Advisers increased its position in shares of XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after purchasing an additional 1,334 shares during the last quarter. State Street Corp raised its stake in shares of XOMA by 1.2% during the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after purchasing an additional 1,754 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after buying an additional 1,968 shares in the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.